in Health care
All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab
New Delhi: Granting the protocol amendment proposal presented by drug major AstraZeneca for anticancer drug Durvalumab, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has stated that all serious adverse events (SAEs) including death irrespective of its cause should be reported to CDSCO as per provision of New Drugs […] More
